Skip to main content

XDx Drops IPO Plans

NEW YORK (GenomeWeb News) – Molecular diagnostics firm XDx has informed the US Securities and Exchange Commission that it is withdrawing its registration statement for an initial public offering.
 
The Brisbane, Calif.-based firm filed for the IPO in October 2007. At the time, the company did not say how many shares it would offer or how much money it expected to raise in the offering. It had expected to use the funds generated by the offering to expand infrastructure, propel R&D to support current and future tests, increase sales, marketing, and research staff, and expand facilities, as well as potential acquisitions.
 
XDx cited “current public market conditions” as the reason for its decision to withdraw the IPO.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.